免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经头条（nbdtoutiao）——中国无人驾驶"军团"，"武装"阿布扎比 （记者 曾健辉） 每经AI快讯，国新健康1月30日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润亏损约 4.09亿元。基本每股收益亏损0.4179元。上年同期归属于上市公司股东的净利润亏损1038万元。基本每 股收益亏损0.0106元。业绩变动主要原因是，报告期内，公司紧紧围绕"健康中国"和"三医协同"改革发 展要求，以"三医协同、创新驱动、数字生态"为战略牵引，围绕医疗卫生行业信息化、数字化、智慧 化，以健康大数据的聚、通、用为主线，聚焦医保基金综合管理服务、医疗质量安全服务、药械监管与 药企服务、健康服务创新，持续挖掘数据价值，积极开展投资合作，为新时代"健康中国"国家战略提供 技术保障和专业服务。报告期内，公司实现营业收入约人民币3.51亿元，基本与上年同期持平；扣除非 经常性损益后的净利润为人民币-1.48亿元，基本与上年同期持平；归属上市公司股东净利润约人民 币-4.09亿元。 ...

Core Viewpoint - Guoxin Health has released a performance forecast, expecting a total operating revenue of 350.77 million yuan for the year 2025, with a focus on health data and digital transformation in the healthcare sector [1] Group 1: Performance Forecast - The company anticipates an operating revenue of approximately 350.77 million yuan for 2025 [1] - The net profit attributable to shareholders is expected to be around -409 million yuan [1] Group 2: Financial Performance - For the first three quarters of 2025, the company's main revenue was 170 million yuan, a year-on-year decrease of 14.87% [2] - The net profit attributable to shareholders for the same period was -138 million yuan, a year-on-year decline of 347.32% [2] - The company's gross profit margin was reported at -5.15% [2] Group 3: Quarterly Performance - In Q3 2025, the company's single-quarter main revenue was 74.87 million yuan, an increase of 19.26% year-on-year [2] - The net profit attributable to shareholders for Q3 was -39.34 million yuan, a year-on-year decrease of 193.59% [2] - The company reported a debt ratio of 37.02% and investment income of 16.57 million yuan [2] Group 4: Reasons for Performance Changes - The increase in losses is primarily due to expected impairment of trading financial assets, particularly related to Shenzhou Medical Technology Co., Ltd., which has seen a decline in operating performance [1]

Core Viewpoint - Guoxin Health expects a total operating revenue of 351 million yuan for the year 2025, maintaining stability compared to the previous year [1] Group 1: Financial Performance - For the first three quarters of 2025, the company's main revenue was 170 million yuan, a year-on-year decrease of 14.87% [2] - The net profit attributable to shareholders was -138 million yuan, a year-on-year decline of 347.32% [2] - The net profit after deducting non-recurring gains and losses was -138 million yuan, a year-on-year decrease of 27.09% [2] - In Q3 2025, the company's single-quarter main revenue was 74.87 million yuan, a year-on-year increase of 19.26% [2] - The single-quarter net profit attributable to shareholders was -39.34 million yuan, a year-on-year decline of 193.59% [2] - The single-quarter net profit after deducting non-recurring gains and losses was -39.37 million yuan, a year-on-year decrease of 29.67% [2] - The company's debt ratio stood at 37.02% [2] - Investment income was 16.57 million yuan, while financial expenses amounted to 6.53 million yuan [2] - The gross profit margin was -5.15% [2] Group 2: Strategic Focus - The company is aligning its operations with the "Healthy China" initiative and the "Three Medical Collaborations" reform, focusing on health data integration and digital transformation [1] - The strategic focus includes comprehensive management services for medical insurance funds, medical quality and safety services, and health service innovation [1] - The company aims to leverage data value and actively pursue investment collaborations to support the national strategy for "Healthy China" [1] Group 3: Asset Impairment - The increase in losses is primarily due to expected impairment of trading financial assets, specifically a 99.01% partnership interest in Shenzhou Borui (Shenzhen) Investment Enterprise [1] - The decline in operating performance of Shenzhou Medical Technology Co., Ltd., in which Shenzhou Borui holds a 7.66% stake, is anticipated to result in a fair value loss of approximately 260 million yuan on the company's trading financial assets [1]

Core Viewpoint - Guoxin Health is expected to report a net profit loss of approximately 148 million RMB for the year 2025 after deducting non-recurring gains and losses, primarily due to impairment losses on financial assets [1] Group 1: Financial Performance - For the year 2025, the company achieved an operating income of approximately 351 million RMB, which is roughly the same as the previous year [1] - The net profit attributable to shareholders of the listed company is approximately -409 million RMB [1] - In the first three quarters of 2025, the company's main revenue was 170 million RMB, a year-on-year decrease of 14.87% [2] - The net profit attributable to shareholders for the same period was -138 million RMB, a year-on-year decrease of 347.32% [2] - The third quarter of 2025 saw a single-quarter main revenue of 74.87 million RMB, a year-on-year increase of 19.26% [2] - The single-quarter net profit attributable to shareholders was -39.34 million RMB, a year-on-year decrease of 193.59% [2] - The company reported a gross margin of -5.15% [2] Group 2: Strategic Focus - The company is aligning its operations with the "Healthy China" initiative and the "Three Medical Collaborations" reform, focusing on healthcare industry informationization, digitalization, and intelligence [1] - The strategic focus includes comprehensive management services for medical insurance funds, medical quality and safety services, drug and device regulation, and health service innovation [1] - The company aims to leverage health big data to provide technical support and professional services for the national strategy of "Healthy China" [1] Group 3: Asset Impairment - The increase in losses is mainly attributed to expected impairment of trading financial assets, specifically a 99.01% partnership interest in Shenzhou Borui (Shenzhen) Investment Enterprise [1] - The impairment is linked to a 7.66% stake in Shenzhou Medical Technology Co., Ltd., which is expected to experience a decline in operating performance and lower-than-expected main business income [1] - The company anticipates a fair value change loss of approximately 260 million RMB related to these trading financial assets [1]

Core Viewpoint - Guoxin Health has released its performance forecast for 2025, expecting a significant decline in net profit attributed to shareholders, projecting a loss of 409.22 million yuan, which represents a year-on-year decrease of 3841.71% [1] Financial Performance - The company anticipates a net profit of -147.88 million yuan after deducting non-recurring gains and losses, reflecting a year-on-year decrease of 2.51% [1] - For the reporting period, the company achieved an operating revenue of approximately 351 million yuan, remaining stable compared to the previous year [1] - The net profit attributable to shareholders is projected to be around -409.22 million yuan, indicating a significant increase in losses [1] Reasons for Performance Changes - The primary reason for the performance decline is the expected impairment of trading financial assets, specifically a 99.01% partnership interest in Shenzhou Borui (Shenzhen) Investment Enterprise [1] - The decline in operating performance of Shenzhou Medical Technology Co., Ltd., in which Shenzhou Borui holds a 7.66% stake, is expected to lead to a fair value loss of approximately 260 million yuan on the company's trading financial assets [1] Strategic Focus - The company is aligning its strategies with the "Healthy China" initiative and the "Three Medical Coordination" reform, focusing on health data integration, management services, and innovative health services [1] - The strategic direction emphasizes digital transformation and the value extraction of health data to support the national strategy for "Healthy China" [1]

国新健康保障服务集团股份有限公司 关于公司持有的交易性金融资产公允价值变动的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 证券简称：国新健康 证券代码：000503 编号：2026-03 1. 本次涉及的交易性金融资产为国新健康保障服务集团股份有限公司（以下 简称"公司"）持有神州博睿（深圳）投资企业（有限合伙）99.01%合伙份额， 神州博睿（深圳）投资企业（有限合伙）持有神州医疗科技股份有限公司（以下 简称"神州医疗"）7.66%股份。 2. 受神州医疗经营业绩下滑影响，预计该交易性金融资产公允价值将出现下 降，对公司本年度净利润产生负面影响，具体影响金额以年度审计结果为准。 截至 2024 年末，该交易性金融资产公允价值为人民币 40,781 万元。根据《企 业会计准则第 22 号——金融工具确认和计量》相关规定，公司将该金融资产分 类为交易性金融资产，以公允价值进行后续计量，公允价值变动计入当期损益。 二、公允价值变动的原因及影响 因神州医疗经营业绩出现下滑，预计 2025 年主营业务收入低于预期，导致 该交易性金融资产公 ...

证券简称：国新健康 证券代码：000503 编号：2026-02 三、业绩变动的主要原因说明 国新健康保障服务集团股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）预计的经营业绩：亏损 | 项 目 | 本报告期 | | 上年同期 | | --- | --- | --- | --- | | 营业收入 | 万元 35,094 | | 万元 35,690 | | 扣除后营业收入 | 万元 35,077 | | 万元 35,673 | | 扣除非经常性损益后的净利润 | 亏损：-14,788 | 万元 | 亏损：-15,167 万元 | | 利润总额 | 亏损：-40,879 | 万元 | 亏损：-1,169 万元 | | 归属于上市公司股东的净利润 | 亏损：-40,922 | 万元 | 亏损：-1,038 万元 | | 基本每股收益 | 亏损：-0.4179 | 元/股 | 亏损：-0.0106 元/股 | 注：扣除 ...

截至发稿，崔蕾累计任职时间7年72天，现任基金资产总规模1227.6亿元，任职期间最佳基金回报 234.52%， 任职期间最差基金回报-15.93%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，南方基金旗下1只基金位居国新健康十大流通股东。南方中证1000ETF（512100）三季度减 持9.06万股，持有股数717.76万股，占流通股的比例为0.73%。根据测算，今日浮亏损失约401.95万元。 连续3天下跌期间浮亏损失574.21万元。 南方中证1000ETF（512100）成立日期2016年9月29日，最新规模766.3亿。今年以来收益8.51%，同类 排名1463/5531；近一年收益44.65%，同类排名1681/4215；成立以来收益24.1%。 南方中证1000ETF（512100）基金经理为崔蕾。 1月16日，国新健康跌5.18%，截至发稿，报10.25元/股，成交2.34亿元，换手率2.28%，总市值100.37亿 元 ...

Group 1 - The AI medical concept is experiencing significant activity, with companies like Dean Diagnostics and Hongbo Pharmaceutical hitting the 20% daily limit increase [1] - Meian Health has achieved a three-day consecutive increase, indicating strong market interest [1] - Other companies such as Jiahe Meikang and Chengdu Xian Dao have seen increases of over 10%, while Anbiping, Weining Health, Yaoshi Technology, and Guoxin Health are also following the upward trend [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券简称：国新健康 证券代码：000503 编号：2026-01 国新健康保障服务集团股份有限公司 4、经核查，公司、控股股东和实际控制人不存在关于本公司应披露而未披露的重大事项，也不存在其 他处于筹划阶段的重大事项。 5、经核查，公司控股股东和实际控制人在股票异常波动期间不存在买卖公司股票的行为。 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股票交易异常波动情况 国新健康保障服务集团股份有限公司（以下简称"公司"）股票交易价格连续3个交易日（2026年1月8 日、2026年1月9日、2026年1月12日）内收盘价涨幅偏离值累计达到20%，根据《深圳证券交易所交易 规则》的相关规定，属于股票交易异常波动的情况。 二、公司关注、核实的情况说明 针对公司股票交易异常波动，公司进行了自查，并向控股股东及实际控制人就相关事项进行了核实，现 就有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大影响的未公 ...